Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s 8.2% Solution: Sequestration Would Cut $319 Million

This article was originally published in The Pink Sheet Daily

Executive Summary

The estimated reduction, included in the White House Office of Management and Budget’s report to Congress, is equal the cost of 900 to 1,200 agency employees, an agency advocate said.

You may also be interested in...



Hamburg, Like Industry, Wants Predictability – But In FDA Funding

Commissioner says the agency cannot operate effectively without predictable budgets and that sequestered user fees are needed now.

FDA User Fee Liberation Likely Hinges On Senate Appropriations Panel

House leadership plans a comprehensive bill to undo sequestration for the government as a whole, but Republican Robert Aderholt, who chairs the House subcommittee that originates appropriations for FDA, says he is willing to work with Senate appropriators in conference on a fix specific to the agency’s user fees.

FDA User Fee Liberation Likely Hinges On Senate Appropriations Panel

House leadership plans a comprehensive bill to undo sequestration for the government as a whole, but Republican Robert Aderholt, who chairs the House subcommittee that originates appropriations for FDA, says he is willing to work with Senate appropriators in conference on a fix specific to the agency’s user fees.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS074646

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel